Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Faull

Pain Medicine Madison, WI Doctor of Osteopathy

NPI 1497910319 CMS profile 1231591

700 S Park St, Suite A, Madison, WI 53715

Open in the dashboard

General payments

$65,743

291 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Faull of Madison, WI is reported in the CMS Open Payments database as having received $65,743 across 291 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,665 22
2024 General $3,378 33
2023 General $9,255 51
2022 General $29,268 81
2021 General $17,035 54
2020 General $3,243 31
2019 General $1,898 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Faull
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Thomas Faull were reported at $1,665. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Thomas Faull Pain Medicine median Middle half National median
2019 $1,898 $506 $144–$1,566 $163
2020 $3,243 $315 $96–$934 $114
2021 $17,035 $452 $134–$1,237 $132
2022 $29,268 $475 $124–$1,407 $149
2023 $9,255 $480 $136–$1,384 $160
2024 $3,378 $521 $164–$1,511 $164
2025 $1,665 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $32,507 59 payments
  2. Abbott Laboratories $13,713 112 payments
  3. Foundation Fusion Solutions, LLC $7,739 30 payments
  4. Nalu Medical, Inc. $3,539 19 payments
  5. SPR Therapeutics, Inc $3,469 23 payments
  6. Vertos Medical, Inc. $1,848 6 payments
  7. Relievant Medsystems, Inc. $903 9 payments
  8. Medtronic USA, Inc. $630 15 payments
  9. Stryker Corporation $493 6 payments
  10. Spinal Simplicity, LLC $259 2 payments
  11. Other $645 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26,100 4 payments
  2. Food and Beverage $15,806 236 payments
  3. Travel and Lodging $8,636 29 payments
  4. Consulting Fee $8,125 7 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $6,641 5 payments
  6. Entertainment $355 9 payments
  7. Education $79 1 payment
Products named General payments · program years 2019–2025
  1. SYNCHROMEDII $23,897 35 payments
  2. Proclaim DRG IPG $6,342 7 payments
  3. OSTEOCOOL RF ABLATION $3,600 1 payment
  4. Nalu Neurostimulation System $3,539 19 payments
  5. SPRINT PNS System $3,469 23 payments
  6. Proclaim IPG $2,549 26 payments
  7. SYNCHROMED $2,250 1 payment
  8. mild Device Kit $1,848 6 payments
  9. Proclaim Family of SCS IPGs $1,692 15 payments
  10. PROCLAIM $1,597 37 payments
  11. Other $8,267 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

150

Median for Pain Management: 951

Drug cost

$1,811

Median for Pain Management: $26,034

Branded share of claims

11.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zonisamide Generic 21 $605
Gabapentin Generic 61 $576
Duloxetine Hcl Generic 27 $351
Cyclobenzaprine Hcl Generic 13 $209
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 17 $65
Alprazolam Generic 11 $4

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$106,493

Of which drugs: $416

Medicare patients

266

Average age 73

Services billed

3,646

165 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 73%
High blood pressure 68%
Depression 35%
Osteoporosis 30%
Diabetes 25%
Ischemic heart disease 23%
Chronic kidney disease 21%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 43 2,150 $214
Injection, methylprednisolone acetate, 40 mg J1030 Office 20 22 $101
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 43 575 $52
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 94 170 $49

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

291 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record